Cogent Biosciences Inc (COGT) Stock Price, Quote & News

Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 5576

Website: www.cogentbio.com

Address:

275 Wyman Street, 3rd Floor, Waltham, United States

highnihilism Sep. 16 at 2:59 PM

Biotech → $ETNB 89Bio $MTSR Metsera $COGT Cogent Biosciences $SNDX Syndax Pharmaceuticals $APLS Apellis Pharmaceuticals

0 · Reply

G101SPM Sep. 9 at 3:15 PM

G101SPM 8/25/2025, 12:26:00 PM $COGT $12.09 bid. DAC (dollar average cost) $7.47 (7.7.25). CHANGE EXIT TO $19.00 FROM $14.00.

0 · Reply

G101SPM Sep. 9 at 3:14 PM

G101SPM 8/25/2025, 10:02:25 AM $COGT $12.15 bid. DAC (dollar average cost) $7.47 (7.7.25). EXIT $14.00. BRIEF: Guggenheim maintains BUY raised target to $20.00

0 · Reply

NVDAMillionaire Sep. 8 at 6:59 PM

$COGT Really good write-up that perfectly summarizes COGT's present situation. So if you want to bring your COGT knowledge up to date or just discover COGT, this is required reading. https://beyondspx.com/quote/COGT/analysis/cogent-biosciences-unlocking-precision-potential-with-bezuclastinib-and-a-deep-pipeline-nasdaq-cogt

0 · Reply

thetrackisfast Sep. 4 at 5:42 AM

$COGT breakout with increased volume

0 · Reply

StockConsultant Sep. 3 at 2:25 PM

$COGT Cogent Biosciences stock, nice top of range breakout, volume +94% at https://stockconsultant.com/?COGT

0 · Reply

OptionRunners Sep. 3 at 2:09 PM

$COGT +11%

0 · Reply

OptionRunners Aug. 28 at 6:55 PM

$COGT Buyer of the December 19th $13C/$20C/$8P bull seagulls 750 times for $1.05. More bullish flow. The September $10 calls are still in the OI, up to about $2.50 now.

0 · Reply

StockConsultant Aug. 27 at 10:48 PM

$COGT Cogent Biosciences stock, good close, watch for a top of range breakout at https://stockconsultant.com/?COGT

0 · Reply

Quantumup Aug. 25 at 12:32 PM

Guggenheim⬆️the PT on $COGT to $20 from $17 and reiterated at a Buy. $PFE $NVS BMPC - $SNY $CLDX DCPH - OPHLY SNDX Guggenheim said in its note:

0 · Reply

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 8:00 AM EDT - 21 days ago

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Aug 5, 2025, 8:00 AM EDT - 6 weeks ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 4:01 PM EDT - 2 months ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 9, 2025, 4:04 PM EDT - 2 months ago

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

Jul 8, 2025, 9:36 PM EDT - 2 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Jul 8, 2025, 4:26 PM EDT - 2 months ago

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Jul 7, 2025, 9:22 AM EDT - 2 months ago

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Jul 7, 2025, 7:06 AM EDT - 2 months ago

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Jun 11, 2025, 8:00 AM EDT - 3 months ago

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

May 29, 2025, 8:00 AM EDT - 3 months ago

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

May 6, 2025, 8:00 AM EDT - 4 months ago

Cogent Biosciences Reports First Quarter 2025 Financial Results

Apr 25, 2025, 8:08 AM EDT - 5 months ago

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Mar 25, 2025, 4:31 PM EDT - 6 months ago

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2025, 8:00 AM EST - 6 months ago

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 7 months ago

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Feb 25, 2025, 8:00 AM EST - 7 months ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 10, 2025, 9:15 AM EST - 7 months ago

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Jan 22, 2025, 12:29 PM EST - 8 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN JAZZ ONC XBI ZYME

Jan 18, 2025, 3:27 AM EST - 8 months ago

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Dec 9, 2024, 7:00 AM EST - 10 months ago

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Dec 8, 2024, 12:00 PM EST - 10 months ago

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Jun 14, 2024, 7:30 AM EDT - 1 year ago

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

May 23, 2024, 5:05 PM EDT - 1 year ago

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

May 23, 2024, 5:01 PM EDT - 1 year ago

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

May 7, 2024, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports First Quarter 2024 Financial Results

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 2:30 PM EST - 1 year ago

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Feb 14, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Feb 5, 2024, 9:00 AM EST - 1 year ago

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Jan 9, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:23 AM EST - 1 year ago

Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment

Dec 11, 2023, 7:55 AM EST - 1 year ago

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 9, 2023, 1:30 PM EST - 1 year ago

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Dec 7, 2023, 9:00 AM EST - 1 year ago

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 15, 2023, 5:03 PM EDT - 2 years ago

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Jul 7, 2023, 11:23 AM EDT - 2 years ago

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

CRC IRWD

Jun 9, 2023, 4:01 PM EDT - 2 years ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

Jun 7, 2023, 9:00 AM EDT - 2 years ago

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

Jun 6, 2023, 4:05 PM EDT - 2 years ago

Cogent Biosciences Announces Proposed Public Offering of Common Stock

Jun 3, 2023, 2:15 PM EDT - 2 years ago

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

May 27, 2023, 7:02 AM EDT - 2 years ago

Cogent Biosciences: APEX Part 2 Launched, ErbB2 And FGFR2 On Track

May 23, 2023, 8:00 AM EDT - 2 years ago

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

highnihilism Sep. 16 at 2:59 PM

Biotech → $ETNB 89Bio $MTSR Metsera $COGT Cogent Biosciences $SNDX Syndax Pharmaceuticals $APLS Apellis Pharmaceuticals

0 · Reply

G101SPM Sep. 9 at 3:15 PM

G101SPM 8/25/2025, 12:26:00 PM $COGT $12.09 bid. DAC (dollar average cost) $7.47 (7.7.25). CHANGE EXIT TO $19.00 FROM $14.00.

0 · Reply

G101SPM Sep. 9 at 3:14 PM

G101SPM 8/25/2025, 10:02:25 AM $COGT $12.15 bid. DAC (dollar average cost) $7.47 (7.7.25). EXIT $14.00. BRIEF: Guggenheim maintains BUY raised target to $20.00

0 · Reply

NVDAMillionaire Sep. 8 at 6:59 PM

0 · Reply

thetrackisfast Sep. 4 at 5:42 AM

$COGT breakout with increased volume

0 · Reply

StockConsultant Sep. 3 at 2:25 PM

$COGT Cogent Biosciences stock, nice top of range breakout, volume +94% at https://stockconsultant.com/?COGT

0 · Reply

OptionRunners Sep. 3 at 2:09 PM

$COGT +11%

0 · Reply

OptionRunners Aug. 28 at 6:55 PM

$COGT Buyer of the December 19th $13C/$20C/$8P bull seagulls 750 times for $1.05. More bullish flow. The September $10 calls are still in the OI, up to about $2.50 now.

0 · Reply

StockConsultant Aug. 27 at 10:48 PM

$COGT Cogent Biosciences stock, good close, watch for a top of range breakout at https://stockconsultant.com/?COGT

0 · Reply

Quantumup Aug. 25 at 12:32 PM

Guggenheim⬆️the PT on $COGT to $20 from $17 and reiterated at a Buy. $PFE $NVS BMPC - $SNY $CLDX DCPH - OPHLY SNDX Guggenheim said in its note:

0 · Reply

JarvisFlow Aug. 25 at 12:30 PM

Guggenheim has updated their rating for Cogent Biosciences ( $COGT ) to Buy with a price target of 20.

0 · Reply

BridgeBeta Aug. 23 at 9:59 AM

$COGT Cogent Biosciences Inc is a clinical stage oncology company with targeted therapy platform

0 · Reply

RonIsWrong Aug. 13 at 2:22 PM

$COGT 👀

0 · Reply

OptionRunners Aug. 12 at 7:09 PM

$COGT Trader sold (to close) the August 15th $10 calls 9,845 times for $1.40 and bought (to open) the September 19th $10 calls 9,845 times for $1.92. The trader is rolling the calls out for a $0.52 debit.

0 · Reply

JarvisFlow Aug. 6 at 12:30 PM

HC Wainwright & Co. has updated their rating for Cogent Biosciences ( $COGT ) to Buy with a price target of 21.

0 · Reply

MGeronimo Aug. 4 at 4:56 PM

$COGT WILL PUSH 52 week on earnings

0 · Reply

MGeronimo Aug. 4 at 4:45 PM

$COGT New 52 week high before earnings

0 · Reply

Cripes84 Aug. 4 at 1:04 PM

$COGT

0 · Reply

MGeronimo Jul. 23 at 5:50 PM

$COGT NEW 52 week high imminent

0 · Reply

BrokNRich Jul. 21 at 1:36 PM

$COGT 1st time on while that i go long on a stock..

1 · Reply

theoptionsplug Jul. 21 at 5:25 AM

The most overbought stocks according to their 14-day RSI: Monogram Technologies $MGRM, Cogent Biosciences Inc $COGT, and Vigil Neuroscience $VIGL The most oversold stocks according to their 14-day RSI: Intapp $INTA and NextNRG $NXXT

0 · Reply

Market Cap	1.44B
Revenue (ttm)	0.00
Net Income (ttm)	-255.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	584,024
Avg Vol	2,840,314
Day's Range	N/A - N/A
Shares Out	113.86M
Stochastic %K	13%
Beta	0.35
Analysts	Strong Sell
Price Target	$21.17